If MYL were to acquire MNTA (assuming for the sake of discussion that MNTA got FDA approval for generic Copaxone and MYL didn’t), MYL would have to divest its existing Copaxone ANDA licensed from Natco. There’s no way the FTC would let MYL retain control of two versions of generic Copaxone.
Market Data 
Markets 
AI
